Cullinan Therapeutics Inc.

09/17/2024 | Press release | Distributed by Public on 09/17/2024 05:10

Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.